carbamates has been researched along with Epilepsy in 66 studies
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since 1955, several alkyl-carbamates have been developed for the treatment of anxiety and epilepsy, including meprobamate, flupirtine, felbamate, retigabine, carisbamate, and cenobamate." | 9.12 | The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? ( Löscher, W; Sills, GJ; White, HS, 2021) |
| "reduction in 28-day total partial seizure frequency of ≥50%) than placebo during both the 12-week maintenance period and the entire 16- or 18-week double-blind phase (i." | 6.47 | Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. ( Deeks, ED, 2011) |
| "Since 1955, several alkyl-carbamates have been developed for the treatment of anxiety and epilepsy, including meprobamate, flupirtine, felbamate, retigabine, carisbamate, and cenobamate." | 5.12 | The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? ( Löscher, W; Sills, GJ; White, HS, 2021) |
| " The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults." | 4.88 | Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. ( Berry, DJ; Patsalos, PN, 2012) |
| " Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals." | 4.88 | ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine). ( Hopkins, CR, 2012) |
| " This compound was effective in delaying onset of PTZ-evoked seizures at the dose of 5mg/kg in kindled animals and significantly reduced oxidative stress better than standard drug phenobarbital (PB)." | 3.81 | Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents. ( Kumari, S; Mishra, CB; Tiwari, M, 2015) |
| " Using a conditional transgenic mouse model, selective ablation of adult neural stem and progenitor cells in the subventricular zone induced a dramatic increase in morbidity and mortality of central nervous system disorders characterized by excitotoxicity-induced cell death accompanied by reactive inflammation, such as 4-aminopyridine-induced epilepsy and ischaemic stroke." | 3.78 | Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity. ( Bacigaluppi, M; Bari, M; Brambilla, E; Butti, E; Cambiaghi, M; Cebrian Silla, A; Centonze, D; Comi, G; D'Adamo, P; De Ceglia, R; De Chiara, V; Garcia-Verdugo, JM; Leocani, L; Maccarrone, M; Martino, G; Musella, A; Muzio, L; Quattrini, A; Rossi, S; Teneud, L, 2012) |
| " Carisbamate reduced the frequency of spontaneous motor seizures in a dose-dependent manner, and was more effective than topiramate at reducing seizures in rats with kainate-induced epilepsy." | 3.74 | A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. ( Dudek, FE; Grabenstatter, HL, 2008) |
| "Adults with uncontrolled focal seizures despite treatment with 1-3 antiepileptic drugs/antiseizure medications (AEDs/ASMs) were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg once daily." | 3.01 | Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study. ( Ferrari, L; Nisman, A; Rosenfeld, WE, 2021) |
| " Consequently, the aim of the current study was to comparatively evaluate the pharmacokinetic (PK) and pharmacodynamic (PD anticonvulsant activity) profile of EMC and IPC individual enantiomers." | 2.79 | Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. ( Bialer, M; Finnell, RH; Mawasi, H; McDonough, JH; Shekh-Ahmad, T; Wlodarczyk, BJ; Yavin, E, 2014) |
| "To achieve seizure freedom in such patients with any modified ASD regimen is an exception." | 2.72 | [Cenobamate-a new perspective for epilepsy treatment]. ( Steinhoff, BJ, 2021) |
| "Epilepsy is one of the most common and disabling chronic neurological disorders." | 2.72 | The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. ( Klein, P; Löscher, W, 2021) |
| "The pooled estimated RR to achieve seizure freedom for the cenobamate group in comparison with placebo was 3." | 2.66 | Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis. ( Brigo, F; Del Giovane, C; Lattanzi, S; Silvestrini, M; Striano, P; Trinka, E; Zaccara, G, 2020) |
| "Ezogabine (D-23129) is a recently approved antiepileptic drug approved by USFDA for adjunctive therapy of partial onset seizures." | 2.49 | Ezogabine: development and role in the management of epileptic seizures. ( Kumar, M; Kumar, R; Verma, A, 2013) |
| "Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs." | 2.48 | Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data. ( Lerche, H; Nies, AT; Orhan, G; Schwab, M; Wuttke, TV, 2012) |
| "reduction in 28-day total partial seizure frequency of ≥50%) than placebo during both the 12-week maintenance period and the entire 16- or 18-week double-blind phase (i." | 2.47 | Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. ( Deeks, ED, 2011) |
| "Eslicarbazepine acetate is a new member of the dibenzazepine family, and blocks the fast inactivated voltage-gated sodium channel." | 2.47 | [New antiepileptic drugs, and therapeutic considerations]. ( Szupera, Z, 2011) |
| "We measured seizure reduction, median reduction in seizure frequency, median dose, responder rate, and treatment-emergent adverse events." | 1.72 | Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study. ( Karkare, S; Kothare, SV; Shah, YD; Varughese, RT, 2022) |
| "Patients with uncontrolled focal seizures despite taking stable doses of 1-3 concomitant antiseizure medications (ASMs) received increasing doses of cenobamate (12." | 1.72 | Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study. ( Abou-Khalil, B; Aboumatar, S; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR, 2022) |
| "Seizures were induced 30 min later using a chemoconvulsant (pentylenetetrazol, PTZ) model, which has been widely used to determine anticonvulsant efficacy of many other antiepileptic drugs in neonatal animals." | 1.38 | Anticonvulsant effect of retigabine during postnatal development in rats. ( Forcelli, PA; Gale, K; Kondratyev, A; Lakhkar, A; Soper, C, 2012) |
| "Female Wistar rats after 90 min of generalized status epilepticus were used." | 1.31 | Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat. ( Brandt, C; Ebert, U; Löscher, W, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (9.09) | 18.7374 |
| 1990's | 5 (7.58) | 18.2507 |
| 2000's | 16 (24.24) | 29.6817 |
| 2010's | 26 (39.39) | 24.3611 |
| 2020's | 13 (19.70) | 2.80 |
| Authors | Studies |
|---|---|
| Specchio, N | 1 |
| Pietrafusa, N | 1 |
| Vigevano, F | 1 |
| Varughese, RT | 1 |
| Shah, YD | 1 |
| Karkare, S | 1 |
| Kothare, SV | 1 |
| Abou-Khalil, B | 1 |
| Aboumatar, S | 1 |
| Klein, P | 2 |
| Krauss, GL | 1 |
| Sperling, MR | 1 |
| Rosenfeld, WE | 2 |
| Ángel Calleja, M | 1 |
| Navarro, A | 1 |
| Serratosa, JM | 1 |
| Toledo, M | 1 |
| Villanueva, V | 1 |
| Subías Labazuy, S | 1 |
| Gil, A | 1 |
| Keam, SJ | 1 |
| Zhao, F | 1 |
| Liu, Y | 1 |
| Dong, H | 1 |
| Feng, S | 1 |
| Shi, G | 1 |
| Lin, L | 1 |
| Tian, Y | 1 |
| Kanyo, R | 1 |
| Wang, CK | 1 |
| Locskai, LF | 1 |
| Li, J | 1 |
| Allison, WT | 1 |
| Kurata, HT | 1 |
| Lattanzi, S | 1 |
| Trinka, E | 1 |
| Zaccara, G | 1 |
| Striano, P | 1 |
| Del Giovane, C | 1 |
| Silvestrini, M | 1 |
| Brigo, F | 1 |
| Soldovieri, MV | 2 |
| Freri, E | 1 |
| Ambrosino, P | 2 |
| Rivolta, I | 1 |
| Mosca, I | 2 |
| Binda, A | 1 |
| Murano, C | 1 |
| Ragona, F | 1 |
| Canafoglia, L | 1 |
| Vannicola, C | 1 |
| Solazzi, R | 1 |
| Granata, T | 1 |
| Castellotti, B | 1 |
| Messina, G | 1 |
| Gellera, C | 1 |
| Labalme, A | 1 |
| Lesca, G | 1 |
| DiFrancesco, JC | 1 |
| Taglialatela, M | 2 |
| Steinhoff, BJ | 1 |
| Löscher, W | 3 |
| Sills, GJ | 1 |
| White, HS | 2 |
| Nisman, A | 1 |
| Ferrari, L | 1 |
| Miceli, F | 1 |
| Manocchio, L | 1 |
| Vanhoof-Villalba, SL | 1 |
| Gautier, NM | 1 |
| Mishra, V | 1 |
| Glasscock, E | 1 |
| Zhou, P | 1 |
| Yu, H | 1 |
| Gu, M | 1 |
| Nan, FJ | 1 |
| Gao, Z | 1 |
| Li, M | 1 |
| Jankovic, S | 1 |
| Ilickovic, I | 1 |
| Hatch, RJ | 1 |
| Reid, CA | 1 |
| Petrou, S | 1 |
| Wehner, T | 1 |
| Chinnasami, S | 1 |
| Novy, J | 1 |
| Bell, GS | 1 |
| Duncan, JS | 1 |
| Sander, JW | 1 |
| Shekh-Ahmad, T | 1 |
| Mawasi, H | 1 |
| McDonough, JH | 1 |
| Finnell, RH | 1 |
| Wlodarczyk, BJ | 1 |
| Yavin, E | 1 |
| Bialer, M | 2 |
| Kumari, S | 1 |
| Mishra, CB | 1 |
| Tiwari, M | 1 |
| Huber, B | 1 |
| Bocchicchio, M | 1 |
| Kalappa, BI | 1 |
| Soh, H | 1 |
| Duignan, KM | 1 |
| Furuya, T | 1 |
| Edwards, S | 1 |
| Tzingounis, AV | 1 |
| Tzounopoulos, T | 1 |
| Smolders, EJ | 1 |
| de Kanter, CT | 1 |
| van 't Veer, N | 1 |
| D'avolio, A | 1 |
| Di Perri, G | 1 |
| Burger, DM | 1 |
| van Wijngaarden, P | 1 |
| Rivera-Arconada, I | 1 |
| Vicente-Baz, J | 1 |
| Lopez-Garcia, JA | 1 |
| Feuerbach, D | 1 |
| Lingenhoehl, K | 1 |
| Olpe, HR | 1 |
| Vassout, A | 1 |
| Gentsch, C | 1 |
| Chaperon, F | 1 |
| Nozulak, J | 1 |
| Enz, A | 1 |
| Bilbe, G | 1 |
| McAllister, K | 1 |
| Hoyer, D | 1 |
| Maljevic, S | 1 |
| Wuttke, TV | 2 |
| Seebohm, G | 1 |
| Lerche, H | 2 |
| Deeks, ED | 1 |
| Szupera, Z | 1 |
| Gunthorpe, MJ | 2 |
| Large, CH | 2 |
| Sankar, R | 3 |
| Sokal, DM | 1 |
| Nehlig, A | 1 |
| Crean, CS | 1 |
| Vanlandingham, KE | 1 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Patsalos, PN | 1 |
| Berry, DJ | 1 |
| Forcelli, PA | 1 |
| Soper, C | 1 |
| Lakhkar, A | 1 |
| Gale, K | 1 |
| Kondratyev, A | 1 |
| Mula, M | 1 |
| Orhan, G | 1 |
| Nies, AT | 1 |
| Schwab, M | 1 |
| Hopkins, CR | 1 |
| Verma, A | 1 |
| Kumar, R | 1 |
| Kumar, M | 1 |
| Butti, E | 1 |
| Bacigaluppi, M | 1 |
| Rossi, S | 1 |
| Cambiaghi, M | 1 |
| Bari, M | 1 |
| Cebrian Silla, A | 1 |
| Brambilla, E | 1 |
| Musella, A | 1 |
| De Ceglia, R | 1 |
| Teneud, L | 1 |
| De Chiara, V | 1 |
| D'Adamo, P | 1 |
| Garcia-Verdugo, JM | 1 |
| Comi, G | 1 |
| Muzio, L | 1 |
| Quattrini, A | 1 |
| Leocani, L | 1 |
| Maccarrone, M | 1 |
| Centonze, D | 1 |
| Martino, G | 1 |
| Ebert, U | 1 |
| Brandt, C | 1 |
| BROUSCHEK, R | 1 |
| FEUERLEIN, W | 1 |
| ABBOTT, JA | 1 |
| SCHOLL, ML | 1 |
| SCHWAB, RS | 1 |
| ENGLAND, AC | 1 |
| DIAMOND, EF | 1 |
| D AMELIO, V | 1 |
| ANNOVI, G | 1 |
| CARTER, CH | 1 |
| Wua, YJ | 1 |
| Dworetzky, SI | 1 |
| Blackburn-Munro, G | 1 |
| Dalby-Brown, W | 1 |
| Mirza, NR | 1 |
| Mikkelsen, JD | 1 |
| Blackburn-Munro, RE | 1 |
| Harrison, PK | 1 |
| Sheridan, RD | 1 |
| Green, AC | 1 |
| Tattersall, JE | 1 |
| Novak, GP | 1 |
| Kelley, M | 1 |
| Zannikos, P | 1 |
| Klein, B | 1 |
| Porter, RJ | 1 |
| Nohria, V | 1 |
| Rundfeldt, C | 5 |
| Kulig, K | 1 |
| Malawska, B | 1 |
| Deshpande, LS | 1 |
| Nagarkatti, N | 1 |
| Ziobro, JM | 1 |
| Sombati, S | 1 |
| DeLorenzo, RJ | 1 |
| Grabenstatter, HL | 1 |
| Dudek, FE | 1 |
| Mazarati, A | 1 |
| Wu, J | 1 |
| Shin, D | 1 |
| Kwon, YS | 1 |
| Dailey, JW | 1 |
| Cheong, JH | 1 |
| Ko, KH | 1 |
| Adams-Curtis, LE | 1 |
| Jobe, PC | 1 |
| Johannessen, SI | 1 |
| Kupferberg, HJ | 1 |
| Levy, RH | 1 |
| Loiseau, P | 1 |
| Perucca, E | 1 |
| Armand, V | 2 |
| Heinemann, U | 2 |
| Thompson, CD | 1 |
| Barthen, MT | 1 |
| Hopper, DW | 1 |
| Miller, TA | 1 |
| Quigg, M | 1 |
| Hudspeth, C | 1 |
| Montouris, G | 1 |
| Marsh, L | 1 |
| Perhach, JL | 1 |
| Sofia, RD | 1 |
| Macdonald, TL | 1 |
| Dost, R | 1 |
| Lawson, K | 1 |
| Cooper, EC | 1 |
| Jannasch, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension[NCT01866111] | Phase 2 | 437 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients achieving a 50% or more reduction from baseline in partial seizure frequency during the double-blind treatment period (NCT01866111)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 23 |
| Cenobamate 100 mg/Day | 44 |
| Cenobamate 200 mg/Day | 63 |
| Cenobamate 400 mg/Day | 67 |
Percent change in complex partial and/or secondarily generalized and/or simple partial motor seizure frequency per 28 days (average 28-day seizure rate) in each treatment group during the double-blind period relative to the pretreatment baseline. (NCT01866111)
Timeframe: baseline and 18 weeks
| Intervention | percent change (Median) |
|---|---|
| Placebo | -24.0 |
| Cenobamate 100 mg/Day | -35.5 |
| Cenobamate 200 mg/Day | -55.0 |
| Cenobamate 400 mg/Day | -55.0 |
23 reviews available for carbamates and Epilepsy
| Article | Year |
|---|---|
Is Cenobamate the Breakthrough We Have Been Wishing for?
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Seizures; Tetrazoles | 2021 |
Cenobamate: First Approval.
Topics: Administration, Oral; Adult; Anticonvulsants; Carbamates; Chlorophenols; Drug Approval; Epilepsies, | 2020 |
Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Drug Therapy, Combination; Epilepsy; Humans; Rand | 2020 |
[Cenobamate-a new perspective for epilepsy treatment].
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Seizures; Tetrazoles | 2021 |
The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ?
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Tetrazoles; Treatment Outcome | 2021 |
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.
Topics: Animals; Anticonvulsants; Bromides; Carbamates; Chlorophenols; Drug Therapy, Combination; Epilepsy; | 2021 |
Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites.
Topics: Animals; Carbamates; Epilepsy; Humans; Indoles; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Me | 2018 |
KV7 channelopathies.
Topics: Animals; Carbamates; Channelopathies; Epilepsy; Humans; KCNQ Potassium Channels; Long QT Syndrome; M | 2010 |
Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.
Topics: Anticonvulsants; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic | 2011 |
[New antiepileptic drugs, and therapeutic considerations].
Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Epilepsy; Humans; Lacosamide; Phenylenediam | 2011 |
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; | 2012 |
Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
Topics: Acetamides; Anticonvulsants; Carbamates; Dibenzazepines; Drug Interactions; Epilepsy; Humans; Lacosa | 2012 |
Recent and future antiepileptic drugs and their impact on cognition: what can we expect?
Topics: Acetamides; Animals; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Epilepsy; Forecast | 2012 |
Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
Topics: Animals; Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Membrane Transport | 2012 |
ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
Topics: Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; Potassium | 2012 |
Ezogabine: development and role in the management of epileptic seizures.
Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Epilepsy; Hal | 2013 |
Recent developments on KCNQ potassium channel openers.
Topics: Acrylamides; Aminopyridines; Benzamides; Carbamates; Epilepsy; Humans; Indoles; Ion Channel Gating; | 2005 |
Retigabine: chemical synthesis to clinical application.
Topics: Animals; Anticonvulsants; Anxiety; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Humans; K | 2005 |
Carisbamate (RWJ-333369).
Topics: Animals; Anticonvulsants; Carbamates; Clinical Trials as Topic; Epilepsy; Humans | 2007 |
Retigabine.
Topics: Animals; Anticonvulsants; Brain; Carbamates; Clinical Trials as Topic; Epilepsy; Humans; Phenylenedi | 2007 |
Is there a role for potassium channel openers in neuronal ion channel disorders?
Topics: Aminopyridines; Animals; Anticonvulsants; Antihypertensive Agents; Ataxia; Carbamates; Diazoxide; Ep | 2000 |
Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs.
Topics: Animals; Anticonvulsants; Carbamates; Clinical Trials as Topic; Drug Design; Epilepsy; Epilepsy, Ben | 2001 |
[Antiepileptics. 39].
Topics: Acetazolamide; Adrenocorticotropic Hormone; Aminoglutethimide; Anticonvulsants; Barbiturates; Carbam | 1969 |
2 trials available for carbamates and Epilepsy
| Article | Year |
|---|---|
Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; E | 2021 |
Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid.
Topics: Animals; Anticonvulsants; Area Under Curve; Carbamates; Central Nervous System; Convulsants; Disease | 2014 |
41 other studies available for carbamates and Epilepsy
| Article | Year |
|---|---|
Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Child; Chlorophenols; Drug Resistant Epilepsy; Epile | 2022 |
Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; Epilepsy | 2022 |
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.
Topics: Adult; Carbamates; Chlorophenols; Cost-Benefit Analysis; Epilepsy; Humans; Lacosamide; Quality-Adjus | 2022 |
An Electrochemophysiological Microarray for Real-Time Monitoring and Quantification of Multiple Ions in the Brain of a Freely Moving Rat.
Topics: Animals; Anticonvulsants; Brain; Calcium; Carbamates; Diamines; Electrochemical Techniques; Epilepsy | 2020 |
Functional and behavioral signatures of Kv7 activator drug subtypes.
Topics: Anilides; Animals; Animals, Genetically Modified; Anticonvulsants; Bridged Bicyclo Compounds; Calciu | 2020 |
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy.
Topics: Age of Onset; Animals; Anticonvulsants; Carbamates; Cells, Cultured; Child; CHO Cells; Cricetinae; C | 2020 |
Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
Topics: Animals; Anticonvulsants; Atrioventricular Block; Behavior, Animal; Bradycardia; Carbamates; Channel | 2018 |
Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
Topics: Animals; Anticonvulsants; Carbamates; CHO Cells; Cricetinae; Cricetulus; Epilepsy; KCNQ2 Potassium C | 2013 |
The preclinical discovery and development of ezogabine for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Drug Discovery; Epilepsy; Humans; Phenylenediamines; Product S | 2013 |
Enhanced in vitro CA1 network activity in a sodium channel β1(C121W) subunit model of genetic epilepsy.
Topics: Action Potentials; Animals; Anticonvulsants; CA1 Region, Hippocampal; Carbamates; Carbamazepine; Dis | 2014 |
Long term retention of retigabine in a cohort of people with drug resistant epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Drug Resistance; Epilepsy; Female; Humans; Lev | 2014 |
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
Topics: Animals; Anticonvulsants; Carbamates; Drug Design; Electroshock; Epilepsy; Mice; Pentylenetetrazole; | 2015 |
A retrospective evaluation of retigabine in patients with cognitive impairment with highly drug-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Cognition; Cognition Disorders; Cohort Studies; Epil | 2015 |
Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
Topics: Animals; Animals, Newborn; Anticonvulsants; Carbamates; Disease Models, Animal; Epilepsy; Evoked Pot | 2015 |
Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine.
Topics: Anticonvulsants; Antiviral Agents; Carbamates; Carbamazepine; Drug Interactions; Drug Therapy, Combi | 2016 |
Targeting Kv7 channels in pain pathways.
Topics: Aminopyridines; Animals; Carbamates; Deafness; Epilepsy; Humans; Inflammation; KCNQ Potassium Channe | 2017 |
The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
Topics: Acoustic Stimulation; alpha7 Nicotinic Acetylcholine Receptor; Analysis of Variance; Animals; Carbam | 2009 |
Deal watch: GSK acquires rights to Valeant's anti-epileptic drug.
Topics: Anticonvulsants; Carbamates; Clinical Trials as Topic; Commerce; Drug Industry; Epilepsy; Legislatio | 2008 |
The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Drug Synergism; Epilepsy; Humans; KCNQ | 2012 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Retigabine: fewer drug interactions.
Topics: Anticonvulsants; Carbamates; Drug Interactions; Drug Therapy, Combination; Epilepsy; Humans; Phenyle | 2012 |
Anticonvulsant effect of retigabine during postnatal development in rats.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Carbamates; Convulsants; Dose-Response Relationsh | 2012 |
Subventricular zone neural progenitors protect striatal neurons from glutamatergic excitotoxicity.
Topics: 4-Aminopyridine; Amidohydrolases; Animals; Arachidonic Acids; Benzamides; Carbamates; Corpus Striatu | 2012 |
Delayed sclerosis, neuroprotection, and limbic epileptogenesis after status epilepticus in the rat.
Topics: Animals; Anticonvulsants; Apoptosis; Biomarkers; Carbamates; Caspase Inhibitors; Dizocilpine Maleate | 2002 |
[Valamin therapy in epilepsy].
Topics: Carbamates; Epilepsy; Humans; Hypnotics and Sedatives | 1956 |
A report on the apparent anticonvulsant effect of hydroxyphenamate (Listica).
Topics: Anticonvulsants; Butylene Glycols; Carbamates; Epilepsy; Tranquilizing Agents | 1962 |
An evaluation of AC-601, a new carbamate anticonvulsant, in the therapy of childhood convulsive disorders.
Topics: Anti-Anxiety Agents; Anticonvulsants; Carbamates; Epilepsy; Esters; Humans; Seizures | 1963 |
[TREATMENT WITH MEBUTAMATE (AN ANTIHYPERTENSIVE WITH CENTRAL ACTION) OF MENTAL PATIENTS WITH HYPERTENSIVE MANIFESTATIONS].
Topics: Alcoholism; Antihypertensive Agents; Anxiety; Bipolar Disorder; Carbamates; Dementia; Epilepsy; Huma | 1963 |
EVALUATION OF 2-HYDROXYETHYL-N-BENZYLCARBAMATE IN EPILEPSY.
Topics: Adolescent; Anticonvulsants; Biomedical Research; Carbamates; Child; Epilepsy; Epilepsy, Absence; Ep | 1964 |
Effects of anticonvulsants on soman-induced epileptiform activity in the guinea-pig in vitro hippocampus.
Topics: Amines; Animals; Anticonvulsants; Carbamates; Carbamazepine; Chlormethiazole; Clozapine; Cyclohexane | 2005 |
Carisbamate, a new carbamate for the treatment of epilepsy.
Topics: Animals; Anticonvulsants; Carbamates; Controlled Clinical Trials as Topic; Disease Models, Animal; D | 2007 |
Carisbamate prevents the development and expression of spontaneous recurrent epileptiform discharges and is neuroprotective in cultured hippocampal neurons.
Topics: Action Potentials; Analysis of Variance; Animals; Animals, Newborn; Anticonvulsants; Carbamates; Cel | 2008 |
A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy.
Topics: Analysis of Variance; Animals; Anticonvulsants; Carbamates; Cross-Over Studies; Disease Models, Anim | 2008 |
Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Carbamates; Disease Models, Ani | 2008 |
Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response.
Topics: Animals; Anticonvulsants; Carbamates; Dose-Response Relationship, Drug; Epilepsy; Female; Male; Phen | 1995 |
Progress report on new antiepileptic drugs: a summary of the Third Eilat Conference.
Topics: Acetamides; Animals; Anticonvulsants; Azetidines; Carbamates; Drug Evaluation, Preclinical; Drugs, I | 1996 |
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; Carbamates; Convulsants; Electrophysiology; | 1999 |
Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids.
Topics: Acetylcysteine; Aldehydes; Animals; Anticonvulsants; Carbamates; Chromatography, High Pressure Liqui | 1999 |
Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells.
Topics: Animals; Anticonvulsants; Carbamates; Cells, Cultured; Electrophysiology; Epilepsy; Nerve Growth Fac | 1999 |
The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation.
Topics: Animals; Anticonvulsants; Calcium; Carbamates; Electrophysiology; Epilepsy; gamma-Aminobutyric Acid; | 2000 |
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Electroencephalography; Entorhinal Cor | 2000 |